乾粉吸入器市場規模、佔有率和成長分析：按產品類型、治療方法、適應症、技術、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球乾粉吸入器 (DPI) 市值為 232.5 億美元，預計到 2025 年將成長至 243.7 億美元，到 2033 年將成長至 12865.8 億美元，在預測期（2026-2033 年將成長至 12865.8 億美元，在預測期（2026-2033 年）內複合年成長率為 4.8%。

由於乾粉吸入器（DPI）無需推進劑粉末狀給藥，用於治療氣喘和慢性阻塞性肺病（COPD）等呼吸系統疾病，其全球市場正經歷顯著成長。該領域的蓬勃發展不僅在於其有效的支氣管擴張作用，還在於與定量噴霧吸入器相比，DPI 的排放量更低，符合環保法規。人口老化和呼吸系統疾病發病率的上升進一步推動了市場需求，尤其是在北美和歐洲。呼吸活化裝置的創新提高了患者的用藥依從性，尤其是老年患者，研究表明，再入院率顯著降低。此外，高濃度乾粉製劑的進步也促進了生物製藥的給藥，拓展了其在癌症和罕見疾病領域的潛在應用。

全球乾粉吸入器市場成長要素

全球乾粉吸入器 (DPI) 市場的主要促進因素是氣喘和慢性阻塞性肺病(COPD) 等呼吸系統疾病的日益流行，這需要高效且便捷的給藥系統。與傳統定量噴霧吸入器相比，DPI 的便攜性、呼吸道連結給藥和易用性等優勢日益受到關注，進一步推動了患者和醫護人員對 DPI 的接受度。此外，吸入器技術的進步，例如藥物配方和裝置設計的改進，透過提高患者依從性和治療效果，也推動了市場成長。

全球乾粉吸入器市場的限制因素

全球乾粉吸入器市場的主要限制因素之一是霧化器和緩霧吸入器等替代給藥系統的日益普及。這些系統使用起來更加便捷，藥物傳輸效率也更高。患者，尤其是患有急性呼吸系統疾病或嚴重氣喘的患者，可能更傾向於選擇這些易於使用的給藥方式。對於那些難以掌握乾粉吸入器正確吸入技巧的患者來說，這一點尤其重要。此外，某些乾粉吸入器高成本，這可能會限制其可及性和市場滲透率，尤其是在新興經濟體，因為在這些地區，價格承受能力是一個主要問題。

全球乾粉吸入器市場趨勢

在全球乾粉吸入器市場，受數位健康技術進步的推動，正經歷著向個人化吸入器平台的動態轉變。製造商正擴大將感測器整合到吸入器中，以測量即時吸入流速，從而提高治療依從性並實現個人化護理。這種技術主導的方法不僅為醫生提供了最佳化治療的寶貴回饋，還透過軟體即服務 (SaaS) 模式開闢了新的收入來源。隨著法規環境的演變以適應連網型設備，那些成功將高品質氣溶膠輸送技術與創新數位健康功能相結合的公司正在獲得競爭優勢，並塑造呼吸系統護理的未來。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系圖譜
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球乾粉吸入器市場規模：依產品類型分類

• 單劑量乾粉吸入器（膠囊型）
• 多劑量乾粉吸入器（儲藥器型）
• 多劑量乾粉吸入器（泡殼包裝）

全球乾粉吸入器市場規模：依治療類型分類

• 維持治療吸入器
• 緊急吸入器

全球乾粉吸入器市場規模：依適應症分類

• 氣喘
• 慢性阻塞性肺病（COPD）
• 囊腫纖維化
• 肺動脈高壓（PAH）
• 糖尿病（吸入式胰島素）
• 其他

全球乾粉吸入器市場規模：依技術分類

• 傳統乾粉吸入器
• 數位/智慧乾粉吸入器

全球乾粉吸入器市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球乾粉吸入器市場規模：依最終用戶分類

• 醫院
• 呼吸專科診所
• 居家照護環境

全球乾粉吸入器市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• GlaxoSmithKline plc
• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• Chiesi Farmaceutici SpA
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Cipla Limited
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Vectura Group plc
• AptarGroup Inc.
• Recipharm AB
• Catalent Inc.
• Kindeva Drug Delivery
• Berry Global Inc.
• Hovione
• Steri-7
• Gerresheimer AG

結論與建議

Global Dry Powder Inhaler Market size was valued at USD 23.25 Billion in 2024 and is poised to grow from USD 24.37 Billion in 2025 to USD 1286.58 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).

The global market for dry powder inhalers (DPIs) is witnessing significant growth due to their role in delivering powdered medications for respiratory conditions like asthma and COPD without propellants. This sector has gained momentum as it not only offers effective bronchodilation but also aligns with environmental regulations by reducing emissions compared to metered-dose inhalers. The increasing aging population and rising rates of respiratory illnesses further drive demand, especially in North America and Europe. Innovations in breath-actuated devices have enhanced patient adherence, particularly among the elderly, while research indicates a notable reduction in hospital readmissions. Additionally, advancements in high-strength dry powder formulations are facilitating the delivery of biologics, thus expanding potential applications in oncology and rare diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dry Powder Inhaler market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dry Powder Inhaler Market Segments Analysis

Global dry powder inhaler market is segmented by product type, therapy type, indication, technology, distribution channel, end user and region. Based on product type, the market is segmented into Single-Dose Dry Powder Inhalers (Capsule-Based), Multi-Dose Dry Powder Inhalers (Reservoir-Based) and Multi-Dose Dry Powder Inhalers (Blister-Based). Based on therapy type, the market is segmented into Maintenance Therapy Inhalers and Rescue Therapy Inhalers. Based on indication, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Arterial Hypertension (PAH), Diabetes (Inhaled Insulin), and Others. Based on technology, the market is segmented into Conventional Dry Powder Inhalers and Digital/Smart Dry Powder Inhalers. Based on distribution channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Respiratory Clinics and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dry Powder Inhaler Market

A key market driver for the global dry powder inhaler (DPI) market is the increasing prevalence of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), which necessitates effective and convenient drug delivery systems. The growing awareness of the benefits of DPIs, including their portability, breath-activated delivery method, and reduced need for coordination compared to traditional metered-dose inhalers, further propels their adoption among patients and healthcare providers. Additionally, advancements in inhaler technology, such as improved formulation of drugs and device designs, enhance patient compliance and offer better therapeutic outcomes, thereby stimulating market growth.

Restraints in the Global Dry Powder Inhaler Market

One key market restraint for the global dry powder inhaler market is the increasing prevalence of alternative drug delivery systems, such as nebulizers and soft mist inhalers, which can offer users a more user-friendly experience and improved medication delivery efficacy. Patients, particularly those with acute respiratory conditions or severe asthma, may prefer these options due to their ease of use, especially for individuals who struggle with proper inhalation techniques required for dry powder inhalers. Additionally, the high costs associated with some dry powder inhalers can limit accessibility and market penetration, particularly in emerging economies where affordability is a significant concern.

Market Trends of the Global Dry Powder Inhaler Market

The Global Dry Powder Inhaler market is witnessing a dynamic shift towards personalized inhaler platforms, driven by advancements in digital health technology. Manufacturers are increasingly integrating sensors into inhalers to capture real-time inhalation flow measurements, enabling enhanced treatment adherence and customization. This tech-driven approach not only provides physicians with valuable feedback for tailoring therapies but also opens new revenue streams through software-as-a-service models. As regulatory environments adapt to accommodate connected devices, companies that successfully merge high-quality aerosol delivery with innovative digital health capabilities are positioning themselves advantageously within the competitive landscape, thus shaping the future of respiratory care.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Dry Powder Inhaler Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Single-Dose Dry Powder Inhalers (Capsule-Based)
• Multi-Dose Dry Powder Inhalers (Reservoir-Based)
• Multi-Dose Dry Powder Inhalers (Blister-Based)

Global Dry Powder Inhaler Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Maintenance Therapy Inhalers
• Rescue Therapy Inhalers

Global Dry Powder Inhaler Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Pulmonary Arterial Hypertension (PAH)
• Diabetes (Inhaled Insulin)
• Others

Global Dry Powder Inhaler Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Conventional Dry Powder Inhalers
• Digital/Smart Dry Powder Inhalers

Global Dry Powder Inhaler Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Dry Powder Inhaler Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Respiratory Clinics
• Homecare Settings

Global Dry Powder Inhaler Market Size & CAGR (2026-2033)

• North America (Product Type, Therapy Type, Indication, Technology, Distribution Channel, End User)
  • US
  • Canada
• Europe (Product Type, Therapy Type, Indication, Technology, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Therapy Type, Indication, Technology, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Therapy Type, Indication, Technology, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Therapy Type, Indication, Technology, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi Farmaceutici S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vectura Group plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AptarGroup Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kindeva Drug Delivery
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Berry Global Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hovione
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Steri-7
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gerresheimer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations